3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neuroblastoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Bacterial Infections
1
Agammaglobulinemia
1
Interventions
Rituximab
59
Cyclophosphamide
35
Vincristine
28
Doxorubicin
24
Prednisone
22
Bendamustine Hydrochloride
17
Etoposide
15
Radiotherapy
12
Cytarabine
10
Peripheral Blood Stem Cell Transplantation
8
Filgrastim
8
ibrutinib
7
VAP-cyclo protocol
7
Prednisolone
7
Methotrexate
7
Granulocyte Colony-Stimulating Factor
7
ibritumomab tiuxetan
6
fludarabine
6
Melphalan
6
Gemcitabine
6
pirtobrutinib
5
Mitoxantrone
5
Lenalidomide
5
Carmustine
5
Bleomycin
5
pixantrone
4
Mycophenolic Acid
4
Methylprednisolone
4
Ifosfamide
4
Idarubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Non-Hodgkin
×
gamma-Globulins
×
Clear all
NCT05645107
2026-04-13
EXCELL
Grifols Therapeutics LLC
Phase 3
Recruiting
386 enrolled